<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546051</url>
  </required_header>
  <id_info>
    <org_study_id>BCI-632-CL-002</org_study_id>
    <nct_id>NCT01546051</nct_id>
  </id_info>
  <brief_title>A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Food Effect of BCI-838; and, An Open-Label Minidose Bioavailability Study to Compare Several BCI-632 Pro-drug Candidates in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BrainCells Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BrainCells Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its&#xD;
      metabolite BCI-632 and several new pro-drugs in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first phase of this study will evaluate the safety and tolerability of BCI-838 following&#xD;
      oral administration of single doses of BCI-838 in healthy male subjects. The pharmacokinetics&#xD;
      of BCI-838 and its metabolite BCI-632 following single ascending doses of BCI-838 will be&#xD;
      evaluated, as will the effect of food on the pharmacokinetics of BCI-838 and its metabolite&#xD;
      following single oral doses of BCI-838 in healthy male subjects.&#xD;
&#xD;
      The second phase of this study will evaluate and compare the relative bioavailability and PK&#xD;
      of the metabolite BCI-632 following single oral administration of several new pro-drug&#xD;
      candidates in healthy male subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>7 days</time_frame>
    <description>Safety will be evaluated by adverse events, vital signs, ECG, clinical labs, and physical exam.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel of BCI-838 and BCI-632</measure>
    <time_frame>predose and at specified intervals up to 72 hours post-dose</time_frame>
    <description>The pharmacokinetics of BCI-838 and its metabolite BCI-632, an assessment of the dose proportionality of the pharmacokinetics following single ascending doses of BCI-838, and an evaluation of the relative bioavailability and pharmacokinetics of the metabolite BCI-632 following oral administration of several new pro-drug candidates will be completed by assessment of Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BCI-838 Food Effect Dosing Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCI-838 Fasted Dosing (100 &amp; 300 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCI-1038, BCI-1206 &amp; BCI-1283</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects will be enrolled, all 6 will receive single doses of BCI-1038, BCI-1206 and BCI-1283.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCI-838 Fasted Dosing (900 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-838</intervention_name>
    <description>BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design</description>
    <arm_group_label>BCI-838 Fasted Dosing (100 &amp; 300 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-838</intervention_name>
    <description>BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design</description>
    <arm_group_label>BCI-838 Food Effect Dosing Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-1038, BCI-1206 &amp; BCI-1283</intervention_name>
    <description>Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design</description>
    <arm_group_label>BCI-1038, BCI-1206 &amp; BCI-1283</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-838</intervention_name>
    <description>BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions</description>
    <arm_group_label>BCI-838 Fasted Dosing (900 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male healthy volunteer, 18-55 years of age&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.0 to 30.0 kg/m2 inclusive&#xD;
&#xD;
          -  Good general health as determined by medical history and physical examination with no&#xD;
             clinically significant medical findings and no clinically relevant medical or surgical&#xD;
             history and no acute or ongoing conditions within the past 30 days&#xD;
&#xD;
          -  Able to participate and willing to give written informed consent and to comply with&#xD;
             the study restrictions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant medical abnormality, chronic disease or history or presence of&#xD;
             significant pulmonary, gastrointestinal, metabolic, cardiac, hepatic, renal or&#xD;
             neurological disorder&#xD;
&#xD;
          -  History or current use of alcohol abuse or drug addiction&#xD;
&#xD;
          -  Participation in a drug study within 60 days prior to drug administration.&#xD;
&#xD;
          -  Participation in more than 3 other drug studies in the 10 months preceding the start&#xD;
             of this study&#xD;
&#xD;
          -  Donation or blood loss of more than 50 mL of blood within 60 days prior to the first&#xD;
             drug administration. Donation of more than 1.5 liters of blood in the 10 months&#xD;
             preceding the start of this study&#xD;
&#xD;
          -  Illness within 5 days prior to drug administration&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>March 6, 2012</last_update_submitted>
  <last_update_submitted_qc>March 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabotropic glutamate receptors 2 and 3</keyword>
  <keyword>antagonist</keyword>
  <keyword>mGluR</keyword>
  <keyword>ketamine</keyword>
  <keyword>BDNF</keyword>
  <keyword>Depression</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Mood Disorder</keyword>
  <keyword>Treatment Resistant Depression</keyword>
  <keyword>Phase 1 safety, tolerability and pharmacokinetics study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCI-838</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

